Literature DB >> 21475956

Variability of plasma homovanillic acid over 13 months in patients with schizophrenia; relationship with the clinical response and the Wisconsin card sort test.

Mercedes Zumárraga1, Miguel A González-Torres, Aurora Arrue, Ricardo Dávila, Wendy Dávila, Lucía Inchausti, Lucía Pérez-Cabeza, Aránzazu Fernández-Rivas, Sonia Bustamante, Nieves Basterreche, José Guimón.   

Abstract

In the present study we have measured, on a monthly basis, the concentration of plasma homovanillic acid (pHVA) in schizophrenic patients during 13 months of their pharmacological treatment. The average pHVA values of each patient were within the range of 7.30-17.70 ng/ml and the coefficients of variation for each patient (CV %) were within the range of 13-33%. Half of the patients that showed higher pHVA CV% values also showed higher scores on the Brief Psychiatric Rating Scale at the beginning of the study, and improved more after 6 months, when compared to the remaining 50% with lower CV% values. There was no significant relationship between the scores of the Wisconsin Card Sort Test and the concentration or the CV% of the pHVA of each patient. A greater variability in the pHVA may be associated with a greater plasticity of the dopaminergic system and a better clinical response.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21475956     DOI: 10.1007/s11064-011-0448-8

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  55 in total

1.  Baseline plasma epinephrine levels predict Wisconsin Card Sorting Test scores in healthy volunteers.

Authors:  Christoph Czermak; Sandra J Wallner; Adelheid Kresse; Silvia Schauer; Reingard Aigner; Gerald Hoefler; Michael Lehofer; Peter M Liebmann
Journal:  Psychoneuroendocrinology       Date:  2008-11-28       Impact factor: 4.905

2.  Plasma HVA, neuroleptics, and dopaminergic plasticity.

Authors:  R Dávila
Journal:  Biol Psychiatry       Date:  1989-01       Impact factor: 13.382

Review 3.  Measurement of plasma homovanillic acid concentrations in schizophrenic patients.

Authors:  R Kaminski; P Powchick; P A Warne; M Goldstein; R T McQueeney; M Davidson
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1990       Impact factor: 5.067

4.  Psychopathological and nutritional correlates of plasma homovanillic acid in adolescents with anorexia nervosa.

Authors:  Josefina Castro-Fornieles; Ramón Deulofeu; Immaculada Baeza; Vanessa Casulà; Begoña Saura; Luisa Lázaro; Josefina Puig; Josep Toro; Miquel Bernardo
Journal:  J Psychiatr Res       Date:  2006-12-01       Impact factor: 4.791

5.  The acute effects of central- and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patients.

Authors:  P E Konicki; R R Owen; R E Litman; D Pickar
Journal:  Life Sci       Date:  1991       Impact factor: 5.037

6.  Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia.

Authors:  Reiji Yoshimura; Nobuhisa Ueda; Koji Shinkai; Jun Nakamura
Journal:  Int Clin Psychopharmacol       Date:  2003-03       Impact factor: 1.659

7.  Plasma homovanillic acid in untreated schizophrenia--relationship with symptomatology and sex.

Authors:  Z J Zhang; M Peet; C N Ramchand; S Shah; G P Reynolds
Journal:  J Psychiatr Res       Date:  2001 Jan-Feb       Impact factor: 4.791

8.  Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients.

Authors:  M Davidson; M F Losonczy; R C Mohs; J C Lesser; P Powchik; L B Freed; B M Davis; V V Mykytyn; K L Davis
Journal:  Neuropsychopharmacology       Date:  1987-12       Impact factor: 7.853

9.  Genetic influences on plasma catecholamines in human twins.

Authors:  P D Williams; I B Puddey; L J Beilin; R Vandongen
Journal:  J Clin Endocrinol Metab       Date:  1993-09       Impact factor: 5.958

10.  Plasma and CSF HVA before and after pharmacological treatment.

Authors:  R Sharma; J I Javaid; P Janicak; K Faull; J Comaty; J M Davis
Journal:  Psychiatry Res       Date:  1989-04       Impact factor: 3.222

View more
  2 in total

1.  Agomelatine Protection in an LPS-Induced Psychosis-Relevant Behavior Model.

Authors:  Sema Inanir; Umit Sertan Copoglu; Hanifi Kokacya; Recep Dokuyucu; Oytun Erbas; Ahmet Inanir
Journal:  Med Sci Monit       Date:  2015-12-08

Review 2.  Presynaptic dopaminergic function: implications for understanding treatment response in psychosis.

Authors:  I Bonoldi; O D Howes
Journal:  CNS Drugs       Date:  2014-07       Impact factor: 5.749

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.